Xenetic Biosciences, Inc.
40 Speen Street
Framingham MA, 01701
biopharmaceutical company focused on progressing XCART™, a personalized CAR-T platform technology engineered to target patient-specific tumor neoantigens. The Company is advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.
Keywords: biopharmaceutical, biotech, bio-tech, car t, B-cell receptor, malignant tumor cells, pharmaceuticals
Copyright ©1995-2021 framingham.com, all rights reserved.
powered by BizDir v.06.03, from LEXIPIXEL